# Outcomes of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: A tertiary center experience

## TL;DR

This study examines how long patients with advanced liver cancer live after receiving a specific treatment called transarterial chemoembolization.

## Contribution

The study provides survival data and identifies factors affecting outcomes in a real-world clinical setting.

## Key findings

- Patients had a median survival of 15 months and a mean survival of 19 months after treatment.
- Child-Pugh classification, tumor size, and embolization pattern significantly influenced survival.
- Transarterial chemoembolization effectively increases survival but does not cure the disease.

## Abstract

To assess the overall survival in patients with intermediate stage hepatocellular carcinoma following transarterial chemoembolization.

It is a retrospective descriptive study carried out in the Department of Radiology of Liaquat National Hospital Karachi, Pakistan. Seventy-two patients were enrolled from July 2014 to December 2021 and had chemoembolization therapy. Patients were followed till their demise. Mean and Median survivals were calculated.

A total of 72 patients had a median survival of 15 months with 95% confidence interval (11 months was lower bound and 18 months was upper bound), 19 months was the mean survival time with 95% confidence interval (14.7 months was lower limit and 22.6 months the upper limit). The factors which had a significant impact on the median survival time were Child-Pugh classification, average size of tumor and embolization pattern.

Transarterial chemoembolization (TACE) increases the median survival time effectively and safely in patients with hepatocellular carcinoma. However complete resolution of disease is not possible with TACE, with most patient eventually succumbing to the disease. The overall survival for TACE in this study correlates well with other studies. Child Pugh Class, tumor size and embolization pattern have significant effect on survival of patients.